Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
66.16
0.03 (0.05%)
Market Cap: 12.61 Bil
Enterprise Value: 12.26 Bil
PE Ratio: 39.62
PB Ratio: 2.33
GF Score: 67/100 
Biomarin Pharmaceutical Inc at Bank of America NAPA Healthcare Conference (Virtual) Transcript
Jun 16, 2021 / 07:30PM GMT
Release Date Price:
$82.48
(+0.63%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Welcome to the afternoon sessions of the third day of the BofA Virtual Napa Conference. I'm Geoff Meacham, I'm the senior biopharma analyst. And I have Aspen Mori from my team with me as well. And we're thrilled to have BioMarin with us. Obviously, we'd all rather be in Napa actually, but not virtually, but it is what it is.
And speaking on behalf of BioMarin, we have Chairman and CEO, J.J. Bienaimé; and we also have Brian Mueller, EVP and CFO. Hey, guys. How's it going?
Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO
Pretty good. Thank you.
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes, we've done a lot of these of late.
Jean;Jacques Bienaime;Geoffrey Christopher Meacham
BioMarin Pharmaceutical Inc. - Chairman & CEO;BofA
(inaudible)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers